 Therapeutic application of opiorphin in humans would require modifying the molecule to avoid its rapid degradation in the intestine and its poor penetration of the blood–brain barrier.This modification is done in the body by transformation of N-terminal glutamine into pyroglutamate.This form preserves the analgesic properties of opiorphin but with increased pharmaceutical stability.